Page 6 - Arcus Bioscience News Today

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the... | June 11, 2023

Updated data from ARC-7, the randomized Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, will be presented in a special ASCO plenary series rapid abstract update session... | May 17, 2023

– Gilead to Have Early Option to Exclusively License Drug Candidates Against up to Four Targets for Inflammatory Diseases – – Expanded Research Collaboration May Result in up to... | May 15, 2023

Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) – Investment analysts at Wedbush dropped their Q2 2023 earnings per share estimates for Arcus Biosciences in a report issued on Wednesday, May 10th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($1.23) per share for the quarter, down from their prior estimate […]

Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. The third dose-escalation cohort of ARC-20 for AB521, a... | May 9, 2023

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the... | May 8, 2023

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the... | April 25, 2023

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the... | April 11, 2023

24.02.2023 - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s ...

Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.